size="10"
The Janssen awards were given on May 9, in the total amount of €60,000, focusing on immunotherapy, neuroscience and infectious diseases.
Professor at the Faculty of Medicine of the University of Lisbon, Bruno Silva-Santos and his team from the João Lobo Antunes iMM, received the first prize in the amount of 30 thousand euros, with the work entitled "Tumour-associated neutrophils suppress pro-tumoral IL-17+ γδ T cells through induction of oxidative stress”. This research has uncovered a group of T lymphocytes that can hinder the body's defences against cancer, yet these cells can be stopped, thus counteracting their negative effect.
The second prize, in the amount of 20 thousand euros was given to the Biomedical Research Centre of the University of the Algarve, and the Faculty of Pharmacy of the University of Coimbra on obesity and metabolic diseases.
About tuberculosis bacterium was the theme of the third prize, developed by the Research Institute for Medicines (iMed.ULisboa) of the Faculty of Pharmacy of the University of Lisbon, in the amount of €10,000.
Due to the quality of the research works under appraisal, four honourable mentions were also awarded.
The Janssen Innovation Award Assessment Committee was chaired by the former President of the Republic, Jorge Sampaio, and an illustrious list of jurors composed of: António Araújo, director of the Medical Oncology Service at the Porto Hospital Centre; Catarina Resende de Oliveira, coordinator of the CNC.IBILI Consortium. João Eurico da Fonseca, director of the Rheumatology Research Unit of the João Lobo Antunes IMM; Professor Rui Baptista , assistant visiting Cardiology professor at the FMUC; José Azevedo Pereira, assistant professor with aggregation, FFUL; Alexandre Castro Caldas, director of the Institute of Health Sciences of the UCP; José Antunes, medical director of Janssen Portugal.
This is now the 2nd edition of the prizes, which are awarded every two years.
Janssen is a global pharmaceutical company that focuses on laboratory research and was founded more than sixty years ago. The ultimate goal is for more drugs to emerge that can respond to various health problems. In Portugal the company has about one hundred employees.
size="20"
